Skip to main content
. Author manuscript; available in PMC: 2011 Nov 4.
Published in final edited form as: Eur J Immunol. 2010 Jul;40(7):1985–1994. doi: 10.1002/eji.200940282

Figure 5. Inhibition of airway inflammation by CTLA4-Ig is dependent on NOS.

Figure 5

Mice of each genotype were systemically sensitized with OVA/Alum then given an inhaled challenge of OVA as described in the Materials and methods. CTLA4-Ig was administered (100 μg, i.p.) on the day of inhaled challenge. Samples were collected for analysis 3 days later. Some mice also received daily injections of (A) 1-MT (10 mg, i.p.) or (B) the NOS inhibitor L-NMMA (2 mg, i.p.) from the time of challenge until harvest. No effect of L-NMMA was seen in mice that did not receive CTLA4-Ig (not shown). Data show mean + SD (n=5), *p<0.05 as compared to mice of the same genotype that received CTLA4-Ig but not L-NMMA. C) H&E-stained lung sections from mice of each group. All data are representative of 3 independent experiments.